HomeAI · summaries
Storia in 5 fonti
Why Is Ionis Pharmaceuticals, AstraZeneca Stock Tumbling Today? - AstraZeneca (NYSE:AZN), Ionis Pharmaceu
Ionis and AstraZeneca said Phase 3 eplontersen missed its primary ATTR-CM endpoint, while secondary measures and safety remained favorable.
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
AstraZeneca, Ionis drug fails big heart disease study in major setback
Eplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and boosted the outlook of rival drugs from Alnylam and…
- ·
endpoints.news
AstraZeneca sinks on unexpected heart drug trial failure
AstraZeneca shares sink up to 9% after Wainua misses cardiovascular endpoint in Phase 3 ATTR-CM trial with partner Ionis.
